244 related articles for article (PubMed ID: 36297446)
1. A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT).
Spoormans K; Crabbé M; Struelens L; De Saint-Hubert M; Koole M
Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297446
[TBL] [Abstract][Full Text] [Related]
2. Introduction to radiobiology of targeted radionuclide therapy.
Pouget JP; Lozza C; Deshayes E; Boudousq V; Navarro-Teulon I
Front Med (Lausanne); 2015; 2():12. PubMed ID: 25853132
[TBL] [Abstract][Full Text] [Related]
3. A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.
Hobbs RF; Baechler S; Fu DX; Esaias C; Pomper MG; Ambinder RF; Sgouros G
Med Phys; 2011 Jun; 38(6):2892-903. PubMed ID: 21815364
[TBL] [Abstract][Full Text] [Related]
4.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
5. Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control Probability.
Falzone N; Lee BQ; Able S; Malcolm J; Terry S; Alayed Y; Vallis KA
J Nucl Med; 2018 Jun; 60(2):250-8. PubMed ID: 29959216
[TBL] [Abstract][Full Text] [Related]
6. The Radiobiology of Radiopharmaceuticals.
Morris ZS; Wang AZ; Knox SJ
Semin Radiat Oncol; 2021 Jan; 31(1):20-27. PubMed ID: 33246632
[TBL] [Abstract][Full Text] [Related]
7. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
Hobbs RF; Howell RW; Song H; Baechler S; Sgouros G
Radiat Res; 2014 Jan; 181(1):90-8. PubMed ID: 24502376
[TBL] [Abstract][Full Text] [Related]
8. Application of a whole-body pharmacokinetic model for targeted radionuclide therapy to NM404 and FLT.
Grudzinski JJ; Floberg JM; Mudd SR; Jeffery JJ; Peterson ET; Nomura A; Burnette RR; Tomé WA; Weichert JP; Jeraj R
Phys Med Biol; 2012 Mar; 57(6):1641-57. PubMed ID: 22398155
[TBL] [Abstract][Full Text] [Related]
9. Voxel-Based Dosimetry of Iron Oxide Nanoparticle-Conjugated
Gupta A; Shin JH; Lee MS; Park JY; Kim K; Kim JH; Suh M; Park CR; Kim YJ; Song MG; Jeong JM; Lee DS; Lee YS; Lee JS
Mol Pharm; 2019 Apr; 16(4):1498-1506. PubMed ID: 30821463
[TBL] [Abstract][Full Text] [Related]
10. Preclinical dosimetric studies of
Meléndez-Alafort L; Ferro-Flores G; Santos-Cuevas C; Ocampo-García B; Turato S; Fracasso G; Bolzati C; Rosato A; De Nardo L
Med Phys; 2021 Jul; 48(7):4064-4074. PubMed ID: 33966284
[TBL] [Abstract][Full Text] [Related]
11. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
12. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.
Wessels BW; Konijnenberg MW; Dale RG; Breitz HB; Cremonesi M; Meredith RF; Green AJ; Bouchet LG; Brill AB; Bolch WE; Sgouros G; Thomas SR
J Nucl Med; 2008 Nov; 49(11):1884-99. PubMed ID: 18927342
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Voxel-Based Dosimetry in Theranostics: a Review.
Gupta A; Lee MS; Kim JH; Lee DS; Lee JS
Nucl Med Mol Imaging; 2020 Apr; 54(2):86-97. PubMed ID: 32377260
[TBL] [Abstract][Full Text] [Related]
14. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in α/β.
Paganetti H
Acta Oncol; 2017 Nov; 56(11):1379-1386. PubMed ID: 28918679
[TBL] [Abstract][Full Text] [Related]
15. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
Bellavia MC; Patel RB; Anderson CJ
J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
[TBL] [Abstract][Full Text] [Related]
16. Preclinical voxel-based dosimetry through GATE Monte Carlo simulation using PET/CT imaging of mice.
Gupta A; Lee MS; Kim JH; Park S; Park HS; Kim SE; Lee DS; Lee JS
Phys Med Biol; 2019 Apr; 64(9):095007. PubMed ID: 30913544
[TBL] [Abstract][Full Text] [Related]
17. Preclinical animal research on therapy dosimetry with dual isotopes.
Konijnenberg MW; de Jong M
Eur J Nucl Med Mol Imaging; 2011 May; 38 Suppl 1(Suppl 1):S19-27. PubMed ID: 21484379
[TBL] [Abstract][Full Text] [Related]
18. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
19. Antitumor efficacy of
Potluri HK; Ferreira CA; Grudzinski J; Massey C; Aluicio-Sarduy E; Engle JW; Kwon O; Marsh IR; Bednarz BP; Hernandez R; Weichert JP; McNeel DG
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36002185
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [
Kim SB; Song IH; Song YS; Lee BC; Gupta A; Lee JS; Park HS; Kim SE
Sci Rep; 2021 Jul; 11(1):15263. PubMed ID: 34315965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
